Cargando…

Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy

BACKGROUND: Glypican-3 (GPC3) is a new prognostic factor after curative hepatectomy in patients with hepatocellular carcinoma (HCC), and the expression of GPC3 is known to be associated with postoperative metastasis. However, the role of GPC3 in patients with early HCC remains unknown. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, I-Pei, Ariizumi, Shun-ichi, Nakano, Masayuki, Yamamoto, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2013
Materias:	Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895193/ https://www.ncbi.nlm.nih.gov/pubmed/23532638 http://dx.doi.org/10.1007/s00535-013-0793-2

Ejemplares similares

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas
por: Shimizu, Takayuki, et al.
Publicado: (2013)

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria
por: Ochi, Hironori, et al.
Publicado: (2020)

Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids
por: Paulo, Joao A, et al.
Publicado: (2012)

Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes
por: Tummala, Pavan, et al.
Publicado: (2013)

A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
por: Cote, Gregory A, et al.
Publicado: (2014)

Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis
por: Zhou, Qunfang, et al.
Publicado: (2022)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
por: Enomoto, Hirayuki, et al.
Publicado: (2020)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
por: Izumi, Namiki, et al.
Publicado: (2012)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan
por: Tateishi, Ryosuke, et al.
Publicado: (2021)

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)
por: Maruki, Yuta, et al.
Publicado: (2020)

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010)

Cholecystectomy or Gallbladder In Situ After Endoscopic Sphincterotomy and Bile Duct Stone Removal in Chinese Patients
por: Lau, James Y.W., et al.
Publicado: (2006)

Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response
por: Tang, Li, et al.
Publicado: (2009)

Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study
por: Shoda, Junichi, et al.
Publicado: (2016)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
por: Okusaka, Takuji, et al.
Publicado: (2021)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
por: Okita, Kiwamu, et al.
Publicado: (2014)

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
por: Tateishi, Ryosuke, et al.
Publicado: (2014)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
por: Okita, Kiwamu, et al.
Publicado: (2014)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020)

Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan
por: Shimakami, Tetsuro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5nor59oimo69ljadovjn4d8hi4